Through joint development with Bacchus Bio innovation, JSR will develop and produce raw materials for its key biomass products utilizing synthetic biology.
The new facility expands the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.
KBI Biopharma, Inc. announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclona...
Crown Bioscience announced today their newly published study in PLOS ONE demonstrating the establishment and application of a clinically relevant 3D in vitro PDX-derived organoid biobank for higher...
This product detects the SARS-CoV-2 and Influenza virus antigen in nasal swab fluid by the immunochromatography method. MBL can sell this product at pharmacies, drugstores and pharmacy online sites.
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced its recently expanded, state-of-the-art Geneva mammalian cell manufacturing facility has obtained a Swissmedic regulatory es...
Medical & Biological Laboratories Co., Ltd. successfully acquired regulatory approval on November 11, 2022 for its SARS-CoV-2 antigen test OTC kit “GLINE-2019-nCoV Agキット（一般用).”
Crown Bioscience have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, which provides the company full license to operate globally using CR...
Tim Lowery, President of JSR Life Sciences, has been named as interim CEO to two of our core Group companies, KBI Biopharma, Inc. and Selexis SA. A search for a permanent CEO is underway.
4 of 23
Receive JSR Life Sciences news on your RSS reader.
